Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Tesis doctoral (DoctoralThesis)

Tumor-on-a-Chip devices for nanomedicine transport evaluation

  • Martín Asensio, Alberto
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Física de la Materia Condensada. Fecha de Lectura: 10-10-2025, Esta Tesis tiene embargado el acceso al texto completo hasta el 10-04-2027, Esta tesis ha sido realizada en el marco del proyecto EVONANO, financiado por el programa Horizon 2020 FET Open de la Unión Europea bajo el acuerdo de subvención No. 800983 y parcialmente financiado por el programa para centros de excelencia de I+D “Severo Ochoa” (MICIN, Subvención CEX2020-001039-S), Programa de Doctorado en Física de la Materia Condensada, Nanociencia y Biofísica
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide

  • Cámara-Sánchez, Patricia
  • Díaz-Riascos, Zamira V.
  • García-Aranda, Natalia
  • Gener, Petra
  • Seras-Franzoso, Joaquin
  • Giani-Alonso, Micaela
  • Royo, Miriam
  • Vázquez, Esther
  • Schwartz Jr., Simó
  • Abasolo, Ibane
Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. Here, we aimed to identify potential drugs targeting CSCs to be further employed in combination with standard chemotherapy in TNBC treatment. The anti-CSC efficacy of up to 17 small drugs was tested in TNBC cell lines using cell viability assays on differentiated cancer cells and CSCs. Then, the effect of 2 selected drugs (8-quinolinol -8Q- and niclosamide -NCS-) in the cancer stemness features were evaluated using mammosphere growth, cell invasion, migration and anchorage-independent growth assays. Changes in the expression of stemness genes after 8Q or NCS treatment were also evaluated. Moreover, the potential synergism of 8Q and NCS with PTX on CSC proliferation and stemness-related signaling pathways was evaluated using TNBC cell lines, CSC-reporter sublines, and CSC-enriched mammospheres. Finally, the efficacy of NCS in combination with PTX was analyzed in vivo using an orthotopic mouse model of MDA-MB-231 cells. Among all tested drug candidates, 8Q and NCS showed remarkable specific anti-CSC activity in terms of CSC viability, migration, invasion and anchorage independent growth reduction in vitro. Moreover, specific 8Q/PTX and NCS/PTX ratios at which both drugs displayed a synergistic effect in different TNBC cell lines were identified. The sole use of PTX increased the relative presence of CSCs in TNBC cells, whereas the combination of 8Q and NCS counteracted this pro-CSC activity of PTX while significantly reducing cell viability. In vivo, the combination of NCS with PTX reduced tumor growth and limited the dissemination of the disease by reducing circulating tumor cells and the incidence of lung metastasis. The combination of 8Q and NCS with PTX at established ratios inhibits both the proliferation of differentiated cancer cells and the viability of CSCs, paving the way for more efficacious TNBC treatments., This work was supported by the Instituto de Salud Carlos III (ISCiii), through Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), an initiative that also counts with the assistance from the European Regional Development Fund (ERDF), specifically in the PENTRI-2 Project and by the “Fundació Marató TV3” (337/C/2013) to I.A., M.R. and E.V. Our laboratories were also supported by the Fondo de Investigaciones Sanitarias (FIS, grants PI20/1474 to S.S.J. and PI18/00871 and PI21/00936), co-financed by the ERDF and the 2017-SGR-638 of the Catalan Government to S.S.J. and EvoNano Project (GA800983), funded by European Union’s Horizon 2020 FET Open Programme. N.G.-A. was supported by grants from Pla Estratègic de Recerca i Innovació en Salut (PERIS) of Catalonia (SLT006/17/00270 270)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Investigation of nanoparticle extravasation pathways in tumor vessel-on-a-chip devices

  • Dávila, Sergio
  • Martín-Asensio, Alberto
  • Sanz-de Diego, Elena
  • Hernández, Jaime J.
  • Rodríguez, Isabel
14 pages, 9 figures, The pathways through which nanomedicines extravasate from the bloodstream into solid tumors remain a subject of active investigation. To elucidate this process, we examine the predominant transport mechanisms in vitro using a tumor-vessel-on-chip (TVoC) microfluidic model device. The device comprises a micro-vessel lined with human umbilical vein endothelial cells, positioned adjacent to a compartment containing a collagen-based extracellular matrix. The two compartments are separated by a row of micropillars, where an endothelial barrier naturally forms at the interface within the gaps. Here, transport of different nanoparticles is analyzed under simulated vascular flow conditions. Strengthening endothelial cell junctions to modulate barrier properties led to a nearly 50 % reduction in the permeability coefficient. Furthermore, disruption of intracellular pathways resulted in minimal nanoparticle permeability, which is consistent with the interpretation that the tested nanoparticles predominantly extravasate via the interendothelial route., A.M.A. acknowledges a predoctoral scholarship from the Severo Ochoa Program for Centers of Excellence in R&D (grant no: PRE2019- 88686) of the Spanish Ministry of Science and Innovation. This research was carried out with funding from the EVONANO project funded by the European Union’s Horizon 2020 FET Open program (Grant agreement No. 800983), and from funding from Spanish Ministry of Science and Innovation (grant No. PID2020-120202RB-I00). IMDEA Nanoscience receives support from the ‘Severo Ochoa’ Programme for Centers of Excellence in R&D (Spanish Ministry of Science and Innovation Grant No. CEX2020-001039-S).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Investigation of nanoparticle extravasation pathways in tumor vessel-on-a-chip devices

  • Dávila, Sergio
  • Martín-Asensio, Alberto
  • Sanz-de Diego, Elena
  • Hernández, Jaime J.
  • Rodríguez, Isabel
14 pages, 9 figures, The pathways through which nanomedicines extravasate from the bloodstream into solid tumors remain a subject of active investigation. To elucidate this process, we examine the predominant transport mechanisms in vitro using a tumor-vessel-on-chip (TVoC) microfluidic model device. The device comprises a micro-vessel lined with human umbilical vein endothelial cells, positioned adjacent to a compartment containing a collagen-based extracellular matrix. The two compartments are separated by a row of micropillars, where an endothelial barrier naturally forms at the interface within the gaps. Here, transport of different nanoparticles is analyzed under simulated vascular flow conditions. Strengthening endothelial cell junctions to modulate barrier properties led to a nearly 50 % reduction in the permeability coefficient. Furthermore, disruption of intracellular pathways resulted in minimal nanoparticle permeability, which is consistent with the interpretation that the tested nanoparticles predominantly extravasate via the interendothelial route., A.M.A. acknowledges a predoctoral scholarship from the Severo Ochoa Program for Centers of Excellence in R&D (grant no: PRE2019- 88686) of the Spanish Ministry of Science and Innovation. This research was carried out with funding from the EVONANO project funded by the European Union’s Horizon 2020 FET Open program (Grant agreement No. 800983), and from funding from Spanish Ministry of Science and Innovation (grant No. PID2020-120202RB-I00). IMDEA Nanoscience receives support from the ‘Severo Ochoa’ Programme for Centers of Excellence in R&D (Spanish Ministry of Science and Innovation Grant No. CEX2020-001039-S).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells

  • Gener, P.
  • Montero, S.
  • Xandri-Monje, H.
  • Díaz-Riascos, Z.V.
  • Rafael, D.
  • Andrade, F.
  • Martínez-Trucharte, F.
  • González, P.
  • Seras-Franzoso, J.
  • Manzano, A.
  • Arango, D.
  • Sayós, J.
  • Abasolo, I.
  • Schwartz, S.Jr
Tumor recurrence, metastatic spread and progressive gain of chemo-resistance of advanced cancers are sustained by the presence of cancer stem cells (CSCs) within the tumor. Targeted therapies with the aim to eradicate these cells are thus highly regarded. However, often the use of new anti-cancer therapies is hampered by pharmacokinetic demands. Drug delivery through nanoparticles has great potential to increase efficacy and reduce toxicity and adverse effects. However, its production has to be based on intelligent design. Likewise, we developed polymeric nanoparticles loaded with Zileuton™, a potent inhibitor of cancer stem cells (CSCs), which was chosen based on high throughput screening. Its great potential for CSCs treatment was subsequently demonstrated in in vitro and in in vivo CSC fluorescent models. Encapsulated Zileuton™ reduces amount of CSCs within the tumor and effectively blocks the circulating tumor cells (CTCs) in the blood stream and metastatic spread.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells

  • Gener, Petra|||0000-0002-2250-570X
  • Rafael, Diana|||0000-0003-3180-3028
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Pérez Martín, Anna
  • Alamo Pindado, Luis
  • Casas, Glòria
  • Arango, Diego|||0000-0003-2953-3284
  • Fernández Caparrós, Yolanda
  • Díaz Riascos, Zamira Vanessa|||0000-0003-1595-618X
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Schwartz, Simon|||0000-0001-8297-7971
Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this subpopulation derives from their dynamic interconversion process, where CSC can differentiate to non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models driven by the expression of ALDH1A 1(aldehyde dehydrogenase 1A1), we confirmed this dynamic phenotypic change in MDA-MB-231 breast cancer cells and to identify Serine/Threonine Kinase 2 (AKT2) as an important player in the process. To confirm the central role of AKT2, we silenced AKT2 expression via small interfering RNA and using a chemical inhibitor (CCT128930), in both CSC and non-CSC from different cancer cell lines. Our results revealed that AKT2 inhibition effectively prevents non-CSC reversion through mesenchymal to epithelial transition, reducing invasion and colony formation ability of both, non-CSC and CSC. Further, AKT2 inhibition reduced CSC survival in low attachment conditions. Interestingly, in orthotopic tumor mouse models, high expression levels of AKT2 were detected in circulating tumor cells (CTC). These findings suggest AKT2 as a promising target for future anti-cancer therapies at three important levels: (i) Epithelial-to-mesenchymal transition (EMT) reversion and maintenance of CSC subpopulation in primary tumors, (ii) reduction of CTC and the likelihood of metastatic spread, and (iii) prevention of tumor recurrence through inhibition of CSC tumorigenic and metastatic potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide

  • Cámara-Sánchez, Patricia|||0000-0003-1958-9735
  • Díaz Riascos, Zamira Vanessa|||0000-0003-1595-618X
  • García Aranda, Natalia|||0000-0003-3230-9881
  • Gener, Petra|||0000-0002-2250-570X
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Giani-Alonso, Micaela
  • Royo, Miriam|||0000-0001-5292-0819
  • Vázquez, Esther|||0000-0003-1052-0424
  • Schwartz, Simon|||0000-0001-8297-7971
  • Abasolo, Ibane|||0000-0001-5970-6276
Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. Here, we aimed to identify potential drugs targeting CSCs to be further employed in combination with standard chemotherapy in TNBC treatment. The anti-CSC efficacy of up to 17 small drugs was tested in TNBC cell lines using cell viability assays on differentiated cancer cells and CSCs. Then, the effect of 2 selected drugs (8-quinolinol -8Q- and niclosamide -NCS-) in the cancer stemness features were evaluated using mammosphere growth, cell invasion, migration and anchorage-independent growth assays. Changes in the expression of stemness genes after 8Q or NCS treatment were also evaluated. Moreover, the potential synergism of 8Q and NCS with PTX on CSC proliferation and stemness-related signaling pathways was evaluated using TNBC cell lines, CSC-reporter sublines, and CSC-enriched mammospheres. Finally, the efficacy of NCS in combination with PTX was analyzed in vivo using an orthotopic mouse model of MDA-MB-231 cells. Among all tested drug candidates, 8Q and NCS showed remarkable specific anti-CSC activity in terms of CSC viability, migration, invasion and anchorage independent growth reduction in vitro. Moreover, specific 8Q/PTX and NCS/PTX ratios at which both drugs displayed a synergistic effect in different TNBC cell lines were identified. The sole use of PTX increased the relative presence of CSCs in TNBC cells, whereas the combination of 8Q and NCS counteracted this pro-CSC activity of PTX while significantly reducing cell viability. In vivo, the combination of NCS with PTX reduced tumor growth and limited the dissemination of the disease by reducing circulating tumor cells and the incidence of lung metastasis. The combination of 8Q and NCS with PTX at established ratios inhibits both the proliferation of differentiated cancer cells and the viability of CSCs, paving the way for more efficacious TNBC treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

  • Ulldemolins, Anna|||0000-0001-8825-9436
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well.